Sequenom Considering Illumina, SOLiD for Down Syndrome Test; Plans to Launch LDT by End of 2011 | GenomeWeb

This article was originally published May 13.

By Julia Karow

Flush with $51.6 million in new funding from a private placement announced last week, Sequenom is forging ahead to develop its non-invasive prenatal trisomy 21 test on a next-generation sequencing platform, its first diagnostic test to use this technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Determining who is and is not an author and where a researcher should fall on a list of authors can be a tricky task, Nature News writes.

In PNAS this week: variant protective against Alzheimer's disease, effect of whole-genome duplication on methylation in rice, and more.

Genome editing is also bringing up questions when applied to farm animals, the New York Times reports.

Through a transcriptome study, researchers home in on the activity of inflammation-linked genes in chronically lonely people.